SUNPHARMAstockSun Pharmaceutical Industries Ltd
₹1,819.95
▲+1.07%
Open
₹1,817.45
High
₹1,822.85
Low
₹1,803.1
Volume
1.81M
Price chart
Daily close · downsampled 5-year history
2021-06-21 · ₹671.252026-06-18 · ₹1,826.95
Instrument details
- MB Code
- MBEQU5368
- Type
- stock
- ISIN
- INE044A01036
- BSE
- 524715
- Industry
- Pharmaceuticals & Biotechnology
Latest earnings
Q4FY26 declared
- Quarter
- Mar 2026
- Revenue
- 14611.79 Cr
- Net profit
- 2723.72 Cr
- EPS
- 11.3
- YoY revenue
- +12.76%
Price returns
Historical performance
- 1 day
- +0.38%
- 1 month
- -2.93%
- 3 months
- +2.78%
- 1 year
- +10.88%
- 3 years
- +82.47%
- 5 years
- +173.33%
Technicals
Indicator consensus
Bullish
35
Neutral
5
Bearish
6
RSI 76.49(Bearish)
Company documents
Annual reports, concalls, presentations
Concall transcripts
48Investor presentations
34Corporate announcements
320Corporate timeline
Price chart events · 1 year
Dividend
2025-07-07
{"amount":5.5}
Dividend
2026-02-05
{"amount":11}
Earnings
2026-01-31
{"actualRevenue":155205400000,"estimateRevenue":149619000000,"revenueSurprise":5586400000,"revenueSurprisePercent":3.733750392664033,"actualEPS":16.03,"estimateEPS":12.87851,"surprise":3.151490000000001,"surprisePercent":24.47092093728235}
Earnings
2025-11-05
{"actualRevenue":144783100000,"estimateRevenue":143361000000,"revenueSurprise":1422100000,"revenueSurprisePercent":0.9919713171643613,"actualEPS":13,"estimateEPS":12.8261617,"surprise":0.1738382999999999,"surprisePercent":1.35534155943161}
Earnings
2026-05-22
{"actualRevenue":146117900000,"estimateRevenue":146713000000,"revenueSurprise":-595100000,"revenueSurprisePercent":-0.4056218603668387,"actualEPS":11.3,"estimateEPS":11.2462288,"surprise":0.05377119999999991,"surprisePercent":0.4781264987246205}
Earnings
2025-07-31
{"actualRevenue":138514000000,"estimateRevenue":138196000000,"revenueSurprise":318000000,"revenueSurprisePercent":0.230107962603838,"actualEPS":12.91,"estimateEPS":12.362905,"surprise":0.5470949999999988,"surprisePercent":4.425294863949846}
News
2026-05-23
{"description":"Sun Pharma reported Q4 FY26 PAT up 26.2% YoY to Rs 2,714 crore, revenue rose 13.6% to Rs 14,559.8 crore, and the board recommended a final dividend of Rs 5 per share.","url":"https://www.businesstoday.in/markets/stocks/story/sun-pharma-q4-pat-up-26-to-rs-2714-crore-announces-final-dividend-check-amount-here-532896-2026-05-22","sentiment":"Positive","domain":"Business Today"}
News
2026-05-22
{"description":"Sun Pharma reported Q4 net profit up 26% to Rs 2,714 crore and its board proposed a Rs 5 final dividend, with India formulations sales rising 14.8% to Rs 4,835.9 crore.","url":"https://www.moneycontrol.com/news/business/earnings/sun-pharma-q4-results-net-profit-jumps-26-to-rs-2-714-crore-board-proposes-rs-5-final-dividend-13928026.html","sentiment":"Positive","domain":"Moneycontrol"}
News
2026-05-22
{"description":"Sun Pharma reported a 26% rise in Q4 net profit, highlighting stronger quarterly earnings for the pharma major. The article does not provide further figures in the headline.","url":"https://www.thehindubusinessline.com/news/national/sun-pharma-q4-net-profit-up-26-per-cent/article71010269.ece","sentiment":"Positive","domain":"The Hindu BusinessLine"}
News
2026-05-03
{"description":"Sun Pharma is exploring Eurobonds and bond swaps to help finance its planned US-based Organon acquisition, with bankers saying it may raise about $10 billion from multiple sources.","url":"https://www.business-standard.com/companies/news/sun-pharma-exploring-eurobonds-bond-swaps-to-fund-us-based-organon-buy-126050300413_1.html","sentiment":"Neutral","domain":"Business Standard"}